Literature DB >> 28067665

Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response.

Cornelis A M van Bergen, Simone A P van Luxemburg-Heijs, Liesbeth C de Wreede, Matthijs Eefting, Peter A von dem Borne, Peter van Balen, Mirjam H M Heemskerk, Arend Mulder, Fransiscus H J Claas, Marcelo A Navarrete, Wilhelmina M Honders, Caroline E Rutten, Hendrik Veelken, Inge Jedema, Constantijn J M Halkes, Marieke Griffioen, J H Frederik Falkenburg.   

Abstract

Patients with leukemia who receive a T cell-depleted allogeneic stem cell graft followed by postponed donor lymphocyte infusion (DLI) can experience graft-versus-leukemia (GVL) reactivity, with a lower risk of graft-versus-host disease (GVHD). Here, we have investigated the magnitude, diversity, and specificity of alloreactive CD8 T cells in patients who developed GVL reactivity after DLI in the absence or presence of GVHD. We observed a lower magnitude and diversity of CD8 T cells for minor histocompatibility antigens (MiHAs) in patients with selective GVL reactivity without GVHD. Furthermore, we demonstrated that MiHA-specific T cell clones from patients with selective GVL reactivity showed lower reactivity against nonhematopoietic cells, even when pretreated with inflammatory cytokines. Expression analysis of MiHA-encoding genes showed that similar types of antigens were recognized in both patient groups, but in patients who developed GVHD, T cell reactivity was skewed to target broadly expressed MiHAs. As an inflammatory environment can render nonhematopoietic cells susceptible to T cell recognition, prevention of such circumstances favors induction of selective GVL reactivity without development of GVHD.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28067665      PMCID: PMC5272193          DOI: 10.1172/JCI86175

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  50 in total

1.  MiXCR: software for comprehensive adaptive immunity profiling.

Authors:  Dmitriy A Bolotin; Stanislav Poslavsky; Igor Mitrophanov; Mikhail Shugay; Ilgar Z Mamedov; Ekaterina V Putintseva; Dmitriy M Chudakov
Journal:  Nat Methods       Date:  2015-05       Impact factor: 28.547

2.  Patient self-management of oral anticoagulation with vitamin K antagonists in everyday practice: comment on Jennings, et al British Journal of Haematology, 2014, 167:600-607.

Authors:  Michael Nagler; Walter A Wuillemin
Journal:  Br J Haematol       Date:  2014-11-19       Impact factor: 6.998

3.  Intestinal Blautia Is Associated with Reduced Death from Graft-versus-Host Disease.

Authors:  Robert R Jenq; Ying Taur; Sean M Devlin; Doris M Ponce; Jenna D Goldberg; Katya F Ahr; Eric R Littmann; Lilan Ling; Asia C Gobourne; Liza C Miller; Melissa D Docampo; Jonathan U Peled; Nicholas Arpaia; Justin R Cross; Tatanisha K Peets; Melissa A Lumish; Yusuke Shono; Jarrod A Dudakov; Hendrik Poeck; Alan M Hanash; Juliet N Barker; Miguel-Angel Perales; Sergio A Giralt; Eric G Pamer; Marcel R M van den Brink
Journal:  Biol Blood Marrow Transplant       Date:  2015-05-11       Impact factor: 5.742

4.  Epstein-Barr virus: transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leukocytes.

Authors:  G Miller; T Shope; H Lisco; D Stitt; M Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1972-02       Impact factor: 11.205

Review 5.  Graft-versus-host disease.

Authors:  Warren D Shlomchik
Journal:  Nat Rev Immunol       Date:  2007-05       Impact factor: 53.106

6.  NetCTLpan: pan-specific MHC class I pathway epitope predictions.

Authors:  Thomas Stranzl; Mette Voldby Larsen; Claus Lundegaard; Morten Nielsen
Journal:  Immunogenetics       Date:  2010-04-09       Impact factor: 2.846

7.  C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients.

Authors:  Scott S Tykodi; Nobuharu Fujii; Nathalie Vigneron; Sharon M Lu; Jeffrey K Mito; Maureen X Miranda; Jeffrey Chou; Lilien N Voong; John A Thompson; Brenda M Sandmaier; Peter Cresswell; Benoît Van den Eynde; Stanley R Riddell; Edus H Warren
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

8.  Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinical application.

Authors:  Marieke Griffioen; H M Esther van Egmond; Helen Barnby-Porritt; Menno A W G van der Hoorn; Renate S Hagedoorn; Michel G D Kester; Nikolai Schwabe; Roel Willemze; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  Haematologica       Date:  2008-09-02       Impact factor: 9.941

9.  CD8+ cell depletion of donor lymphocyte infusions using cd8 monoclonal antibody-coated high-density microparticles (CD8-HDM) after allogeneic hematopoietic stem cell transplantation: a pilot study.

Authors:  E P Alyea; C Canning; D Neuberg; H Daley; H Houde; S Giralt; R Champlin; K Atkinson; R J Soiffer
Journal:  Bone Marrow Transplant       Date:  2004-07       Impact factor: 5.483

10.  Microarray Gene Expression Analysis to Evaluate Cell Type Specific Expression of Targets Relevant for Immunotherapy of Hematological Malignancies.

Authors:  M J Pont; M W Honders; A N Kremer; C van Kooten; C Out; P S Hiemstra; H C de Boer; M J Jager; E Schmelzer; R G Vries; A S Al Hinai; W G Kroes; R Monajemi; J J Goeman; S Böhringer; W A F Marijt; J H F Falkenburg; M Griffioen
Journal:  PLoS One       Date:  2016-05-12       Impact factor: 3.240

View more
  40 in total

Review 1.  Prevention of relapse after allogeneic hematopoietic cell transplantation by donor and cell source selection.

Authors:  Katharina Fleischhauer; Katharine C Hsu; Bronwen E Shaw
Journal:  Bone Marrow Transplant       Date:  2018-05-24       Impact factor: 5.483

Review 2.  Exploiting non-canonical translation to identify new targets for T cell-based cancer immunotherapy.

Authors:  Céline M Laumont; Claude Perreault
Journal:  Cell Mol Life Sci       Date:  2017-08-19       Impact factor: 9.261

3.  Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Authors:  Nimitha R Mathew; Francis Baumgartner; Lukas Braun; David O'Sullivan; Simone Thomas; Miguel Waterhouse; Tony A Müller; Kathrin Hanke; Sanaz Taromi; Petya Apostolova; Anna L Illert; Wolfgang Melchinger; Sandra Duquesne; Annette Schmitt-Graeff; Lena Osswald; Kai-Li Yan; Arnim Weber; Sonia Tugues; Sabine Spath; Dietmar Pfeifer; Marie Follo; Rainer Claus; Michael Lübbert; Christoph Rummelt; Hartmut Bertz; Ralph Wäsch; Johanna Haag; Andrea Schmidts; Michael Schultheiss; Dominik Bettinger; Robert Thimme; Evelyn Ullrich; Yakup Tanriver; Giang Lam Vuong; Renate Arnold; Philipp Hemmati; Dominik Wolf; Markus Ditschkowski; Cordula Jilg; Konrad Wilhelm; Christian Leiber; Sabine Gerull; Jörg Halter; Claudia Lengerke; Thomas Pabst; Thomas Schroeder; Guido Kobbe; Wolf Rösler; Soroush Doostkam; Stephan Meckel; Kathleen Stabla; Stephan K Metzelder; Sebastian Halbach; Tilman Brummer; Zehan Hu; Joern Dengjel; Björn Hackanson; Christoph Schmid; Udo Holtick; Christof Scheid; Alexandros Spyridonidis; Friedrich Stölzel; Rainer Ordemann; Lutz P Müller; Flore Sicre-de-Fontbrune; Gabriele Ihorst; Jürgen Kuball; Jan E Ehlert; Daniel Feger; Eva-Maria Wagner; Jean-Yves Cahn; Jacqueline Schnell; Florian Kuchenbauer; Donald Bunjes; Ronjon Chakraverty; Simon Richardson; Saar Gill; Nicolaus Kröger; Francis Ayuk; Luca Vago; Fabio Ciceri; Antonia M Müller; Takeshi Kondo; Takanori Teshima; Susan Klaeger; Bernhard Kuster; Dennis Dong Hwan Kim; Daniel Weisdorf; Walter van der Velden; Daniela Dörfel; Wolfgang Bethge; Inken Hilgendorf; Andreas Hochhaus; Geoffroy Andrieux; Melanie Börries; Hauke Busch; John Magenau; Pavan Reddy; Myriam Labopin; Joseph H Antin; Andrea S Henden; Geoffrey R Hill; Glen A Kennedy; Merav Bar; Anita Sarma; Donal McLornan; Ghulam Mufti; Betul Oran; Katayoun Rezvani; Omid Shah; Robert S Negrin; Arnon Nagler; Marco Prinz; Andreas Burchert; Andreas Neubauer; Dietrich Beelen; Andreas Mackensen; Nikolas von Bubnoff; Wolfgang Herr; Burkhard Becher; Gerard Socié; Michael A Caligiuri; Eliana Ruggiero; Chiara Bonini; Georg Häcker; Justus Duyster; Jürgen Finke; Erika Pearce; Bruce R Blazar; Robert Zeiser
Journal:  Nat Med       Date:  2018-02-12       Impact factor: 53.440

Review 4.  T cell optimization for graft-versus-leukemia responses.

Authors:  Melinda A Biernacki; Vipul S Sheth; Marie Bleakley
Journal:  JCI Insight       Date:  2020-05-07

Review 5.  Graft versus tumor effects and why people relapse.

Authors:  J H Frederik Falkenburg; Inge Jedema
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

6.  αβ T-cell graft depletion for allogeneic HSCT in adults with hematological malignancies.

Authors:  Moniek A de Witte; Anke Janssen; Klaartje Nijssen; Froso Karaiskaki; Luuk Swanenberg; Anna van Rhenen; Rick Admiraal; Lotte van der Wagen; Monique C Minnema; Eefke Petersen; Reinier A P Raymakers; Kasper Westinga; Trudy Straetemans; Constantijn J M Halkes; Jaap-Jan Boelens; Jürgen Kuball
Journal:  Blood Adv       Date:  2021-01-12

7.  Allogeneic Tumor Antigen-Specific T Cells for Broadly Applicable Adoptive Cell Therapy of Cancer.

Authors:  Zaki Molvi; Richard J O'Reilly
Journal:  Cancer Treat Res       Date:  2022

8.  Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia.

Authors:  Dyantha I van der Lee; Rogier M Reijmers; Maria W Honders; Renate S Hagedoorn; Rob Cm de Jong; Michel Gd Kester; Dirk M van der Steen; Arnoud H de Ru; Christiaan Kweekel; Helena M Bijen; Inge Jedema; Hendrik Veelken; Peter A van Veelen; Mirjam Hm Heemskerk; J H Frederik Falkenburg; Marieke Griffioen
Journal:  J Clin Invest       Date:  2019-01-14       Impact factor: 14.808

9.  A broad and systematic approach to identify B cell malignancy-targeting TCRs for multi-antigen-based T cell therapy.

Authors:  Miranda H Meeuwsen; Anne K Wouters; Lorenz Jahn; Renate S Hagedoorn; Michel G D Kester; Dennis F G Remst; Laura T Morton; Dirk M van der Steen; Christiaan Kweekel; Arnoud H de Ru; Marieke Griffioen; Peter A van Veelen; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  Mol Ther       Date:  2021-08-08       Impact factor: 11.454

Review 10.  Allogeneic Stem Cell Transplantation Platforms With Ex Vivo and In Vivo Immune Manipulations: Count and Adjust.

Authors:  Moniek de Witte; Laura G M Daenen; Lotte van der Wagen; Anna van Rhenen; Reiner Raymakers; Kasper Westinga; Jürgen Kuball
Journal:  Hemasphere       Date:  2021-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.